ArticleCancer2018
PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Article in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- The Role of Artificial Neural Networks in Prostate Magnetic Resonance Imaging (MRI) Segmentation.Cureus · 2026Article
- Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort Study.Cancer research communications · 2026Article
- Identification of biomarkers for non-invasive diagnosis and risk stratification in prostate cancer using NMR-based metabolomics and machine learning.NPJ precision oncology · 2026Article
- Changes in PSA-Based Early Detection of Prostate Cancer over a 12-Year Period: Findings from the German KABOT Study.Healthcare (Basel, Switzerland) · 2026Article
- Prostate Specific Antigen Ordering After Implementation of a Point-of-Care Reminder to Discuss Screening.Journal of the American Board of Family Medicine : JABFM · 2026Article
- Applications of Plant Lectins in Detection and Targeted Therapy of Urological Cancers.Drug design, development and therapy · 2026Review
- Fee cuts for radiology and low-value imaging.International journal of health economics and management · 2025Article
- Comparison Between a New PSA Assay With the Well-Established Beckman Coulter Immunoassay: A Preliminary Report.Analytical science advances · 2025Article
- Optimizing Prostate Cancer Diagnostic Work-Up Through Micro-Ultrasound: Minimizing Unnecessary Procedures and Reducing Overdiagnoses.The Prostate · 2025Article
- Chronological Trends of PSA Levels at Diagnosis in Population-based Prostate Cancer Data 2004-2021, a Time Period of Drastic Changes in Screening Guidelines: Potential Implications in Prostate Cancer Diagnosis.Journal of registry management · 2025Article
- Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states.AIDS care · 2024Article
- Low-Value Prostate Cancer Screening Among Young Men With Private Insurance.Urology practice · 2024Article
- The use of PSA testing over more than 20 years: A population-based study in North-Eastern Italy.Tumori · 2023Article
- Associations of Content and Context of Communication with Prostate-Specific Antigen Testing.International journal of environmental research and public health · 2023Article
- Trends in Urethral Suspension With Robotic Prostatectomy Procedures Following Medicare Payment Policy Changes.JAMA network open · 2022Article
- Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations.BMC urology · 2022Article
- Identification of characteristic metabolic panels for different stages of prostate cancer byJournal of translational medicine · 2022Article
- Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.JAMA network open · 2022Article
- Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer.Investigative and clinical urology · 2022Article
- Trends in Incidence of Metastatic Prostate Cancer in the US.JAMA network open · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2012 United States Preventive Services Task Force recommendation against screening for prostate cancer has impacted rates of prostate-specific antigen (PSA) screening and appears to be associated with declining prostate cancer incidence. Our objective was to characterize health care utilization that may explain these observed trends.
methodsMarketScan claims, which capture >30 million privately insured patients in the United States, were queried for all men aged 40-64 years for the years 2008-2014. PSA testing, prostate biopsy, prostate cancer diagnosis, and definitive local treatment were determined using associated International Classification of Diseases, Ninth Revision and Current Procedural Terminology, Fourth Edition codes.
resultsThere were approximately 6 million qualifying men with a full year of data. PSA testing, prostate biopsy, and prostate cancer detection declined significantly between 2009 and 2014, most notably after 2011. The prostate biopsy rate per 100 patients with a PSA test decreased over the study period from 1.95 (95% confidence interval [CI], 1.92-1.97) to 1.52 (95% CI, 1.50-1.54). Prostate cancer incidence per prostate biopsy increased over the study period from 0.36 (95% CI, 0.35-0.36) to 0.39 (95% CI, 0.39-0.40). Of new prostate cancer diagnoses, the proportion managed with definitive local treatment decreased from 69% (95% CI, 69%-70%) to 54% (95% CI, 53%-55%). Both PSA testing and prostate cancer incidence decreased significantly after 2011 (P < .001).
conclusionIn a large cohort of privately insured men, PSA testing, prostate biopsy, prostate cancer incidence, and local definitive treatment for prostate cancer decreased between 2008 and 2014, most notably after 2011. This decrease may be driven by differential referral patterns from primary care providers to urologists. Cancer 2018;124:2733-2739. © 2018 American Cancer Society.
Indexed as
Identifiers
29781117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.